Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Impact of postoperative duration of Aspirin use on longevity of bioprosthetic pulmonary valve in patients who underwent congenital heart disease repair

  • Hwang, Tae-Woong (Department of Pediatrics, Sejong General Hospital) ;
  • Kim, Sung-Ook (Department of Pediatrics, Sejong General Hospital) ;
  • Lee, Sang-Yun (Department of Pediatrics, Sejong General Hospital) ;
  • Kim, Seong-Ho (Department of Pediatrics, Sejong General Hospital) ;
  • Choi, Eun-Young (Department of Pediatrics, Sejong General Hospital) ;
  • Jang, So-Ick (Department of Pediatrics, Sejong General Hospital) ;
  • Park, Su-Jin (Department of Pediatrics, Sejong General Hospital) ;
  • Kwon, Hye-Won (Department of Pediatrics, Sejong General Hospital) ;
  • Lim, Hyo-Bin (Department of Pediatrics, Sejong General Hospital) ;
  • Lee, Chang-Ha (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital) ;
  • Choi, Eun-Seok (Department of Thoracic and Cardiovascular Surgery, Sejong General Hospital)
  • 투고 : 2016.08.07
  • 심사 : 2016.09.12
  • 발행 : 2016.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Generally, aspirin is used as a protective agent against thrombogenic phenomenon after pulmonary valve replacement (PVR) using a bioprosthetic valve. However, the appropriate duration of aspirin use is unclear. We analyzed the impact of postoperative duration of aspirin use on the longevity of bioprosthetic pulmonary valves in patients who underwent repair for congenital heart diseases. Methods: We retrospectively reviewed the clinical data of 137 patients who underwent PVR using a bioprosthetic valve between January 2000 and December 2003. Among these patients, 89 were included in our study and divided into groups I (${\leq}12$ months) and II (>12 months) according to duration of aspirin use. We analyzed echocardiographic data from 9 to 11 years after PVR. Pulmonary vale stenosis and regurgitation were classified as mild, moderate, or severe. Results: The 89 patients consisted of 53 males and 36 females. Their mean age was $14.3{\pm}8.9$ years (range, 2.6-48 years) and body weight was $37.6{\pm}14.7kg$ (range, 14-72 kg). The postoperative duration of aspirin use was $7.3{\pm}2.9$ months in group I and $32.8{\pm}28.4$ months in group II. However, no significant difference in sex ratio, age, body weight, type of bioprosthetic valve, and number of early redo-PVRs. In the comparison of echocardiographic data about 10 years later, no significant difference in pulmonary valve function was found. The overall freedom rate from redo-PVR at 10 years showed no significant difference (P=0.498). Conclusion: Our results indicated no benefit from long-term aspirin medication (>6 months) in patients who underwent PVR with a bioprosthetic valve.

키워드

참고문헌

  1. Aramendi JI, Mestres CA, Campos V, Martinez-Leon J, Pontes C, Munoz G, et al. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): rationale and design for a prospective, randomized, co-operative trial. Interact Cardiovasc Thorac Surg 2003;2:170-4. https://doi.org/10.1016/S1569-9293(03)00010-0
  2. Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, Alexander JH. Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. J Thromb Thrombolysis 2011;31:514-22. https://doi.org/10.1007/s11239-011-0574-9
  3. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation 1989;80:1501-13. https://doi.org/10.1161/01.CIR.80.6.1501
  4. McClung JA, Stein JH, Ambrose JA, Herman MV, Reed GE. Prosthetic heart valves: a review. Prog Cardiovasc Dis 1983;26:237-70. https://doi.org/10.1016/0033-0620(83)90008-7
  5. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 1986;8(6 Suppl B):41B-56B. https://doi.org/10.1016/S0735-1097(86)80006-7
  6. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 2001;37:569-78. https://doi.org/10.1016/S0735-1097(00)01135-9
  7. Giglia TM, Massicotte MP, Tweddell JS, Barst RJ, Bauman M, Erickson CC, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation 2013;128:2622-703. https://doi.org/10.1161/01.cir.0000436140.77832.7a
  8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2438-88. https://doi.org/10.1016/j.jacc.2014.02.537
  9. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). G Ital Cardiol (Rome) 2013;14:167-214.
  10. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 (2 Suppl):e576S-600S. https://doi.org/10.1378/chest.11-2305
  11. Geva T. Indications for pulmonary valve replacement in repaired tetralogy of fallot: the quest continues. Circulation 2013;128: 1855-7. https://doi.org/10.1161/CIRCULATIONAHA.113.005878
  12. Lee C, Park CS, Lee CH, Kwak JG, Kim SJ, Shim WS, et al. Durability of bioprosthetic valves in the pulm onary position: long-term follow-up of 181 implants in patients with congenital heart disease. J Thorac Cardiovasc Surg 2011;142:351-8. https://doi.org/10.1016/j.jtcvs.2010.12.020
  13. Caldarone CA, McCrindle BW, Van Arsdell GS, Coles JG, Webb G, Freedom RM, et al. Independent factors associated with longevity of prosthetic pulmonary valves and valved conduits. J Thorac Cardiovasc Surg 2000;120:1022-30. https://doi.org/10.1067/mtc.2000.110684
  14. Simionescu DT. Prevention of calcification in bioprosthetic heart valves: challenges and perspectives. Expert Opin Biol Ther 2004; 4:1971-85. https://doi.org/10.1517/14712598.4.12.1971
  15. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. Studies on human naturally occurring antibodies to pig xenografts. Transplant Proc 1993;25:2917-8.
  16. Fann JI, Miller DC, Moore KA, Mitchell RS, Oyer PE, Stinson EB, et al. Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg 1996;62:1301-11. https://doi.org/10.1016/0003-4975(96)00629-7